|
|
Blood, 15 August 2007, Vol. 110, No. 4, pp. 1098-1104.
Prepublished online as a Blood First Edition Paper on May 9, 2007; DOI 10.1182/blood-2007-03-067710.
 Previous Article | Table of Contents | Next Article 
REVIEW IN TRANSLATIONAL HEMATOLOGY
Myeloma bone disease and proteasome inhibition therapies
Evangelos Terpos1,2,
Orhan Sezer3,
Peter Croucher4, and
Meletios-Athanassios Dimopoulos5
1 Department of Hematology and Medical Research, 251 General Airforce Hospital, Athens, Greece;
2 Department of Hematology, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, United Kingdom;
3 Department of Hematology and Oncology, Charité-Universitaetsmedizin Berlin, Berlin, Germany;
4 Academic Unit of Bone Biology, Section of Musculoskeletal Science, University of Sheffield Medical School, Sheffield, United Kingdom;
5 Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece
Bone disease is one of the most debilitating manifestations of multiple myeloma. A complex interdependence exists between myeloma bone disease and tumor growth, creating a vicious circle of extensive bone destruction and myeloma progression. Proteasome inhibitors have recently been shown to promote bone formation in vitro and in vivo. Preclinical studies have demonstrated that proteasome inhibitors, including bortezomib, which is the first-in-class such agent, stimulate osteoblast differentiation while inhibiting osteoclast formation and bone resorption. Clinical studies are confirming these observations. Bortezomib counteracts the abnormal balance of osteoclast regulators (receptor activator of nuclear factor- B ligand and osteoprotegerin), leading to osteoclast inhibition and decreased bone destruction, as measured by a reduction in markers of bone resorption. In addition, bortezomib stimulates osteoblast function, possibly through the reduction of dickkopf-1, leading to increased bone formation, as indicated by the elevation in bone-specific alkaline phosphatase and osteocalcin. The effect of bortezomib on bone disease is thought to be direct and not only a consequence of the agent's antimyeloma properties, making it an attractive agent for further investigation, as it may combine potent antimyeloma activity with beneficial effects on bone. However, the clinical implication of these effects requires prospective studies with specific clinical end points.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy Jr, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, et al.
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Blood,
September 3, 2009;
114(10):
2068 - 2076.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Deleu, M. Lemaire, J. Arts, E. Menu, E. Van Valckenborgh, I. Vande Broek, H. De Raeve, L. Coulton, B. Van Camp, P. Croucher, et al.
Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
Cancer Res.,
July 1, 2009;
69(13):
5307 - 5311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-W. Qiang, B. Hu, Y. Chen, Y. Zhong, B. Shi, B. Barlogie, and J. D. Shaughnessy Jr
Bortezomib induces osteoblast differentiation via Wnt-independent activation of {beta}-catenin/TCF signaling
Blood,
April 30, 2009;
113(18):
4319 - 4330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sezer
Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment
Oncologist,
March 1, 2009;
14(3):
276 - 283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Laronne-Bar-On, D. Zipori, and N. Haran-Ghera
Increased Regulatory versus Effector T Cell Development Is Associated with Thymus Atrophy in Mouse Models of Multiple Myeloma
J. Immunol.,
September 1, 2008;
181(5):
3714 - 3724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. T. Shu, M. V.P. Nadella, W. P. Dirksen, S. A. Fernandez, N. K. Thudi, J. L. Werbeck, M. D. Lairmore, and T. J. Rosol
A Novel Bioluminescent Mouse Model and Effective Therapy for Adult T-Cell Leukemia/Lymphoma
Cancer Res.,
December 15, 2007;
67(24):
11859 - 11866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
